A Phase 1 interventional study of Etavopivat and Moxifloxacin in Healthy Volunteers, Sickle Cell Disease and Thalassemia, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S — 4 open to participants now, 5 under way, 3 of them phase 3. Anemia, Sickle Cell · Novo Nordisk A/S.
Among the 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S, this one is the 8th largest by enrollment, is one of 3 that started in 2025, is one of 3 in phase 1, and was the 11th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →4 of the 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Australia, Belgium and 18 more countries
Ages 12+
Novo Nordisk A/S · Sites in United States, Canada, Egypt and 14 more countries
Ages 2+
Forma Therapeutics, Inc. · Sites in India, Nigeria, Oman
Ages 12–16
Forma Therapeutics, Inc. · Sites in Canada, France, Kenya and 4 more countries
Ages 6 mo–18 yrs
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2025.
This study's enrollment of 33 is below the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 95 across the 11 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
2 of the studies in Anemia, Sickle Cell by Novo Nordisk A/S that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06612268Phase 3Novo Nordisk A/SA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | 2027-08-27 |
| NCT05953584Forma Therapeutics, Inc.A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke | 2027-08-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk is developing a new study medicine, Etavopivat, to treat individuals with sickle cell disease (SCD). The purpose of the study is to determine the effect of Etavopivat on the electrical activity of the heart in healthy participants. The study comprises two parts: Part A and Part B. Part A investigates the safety of a high dose of Etavopivat. In this phase, participants will receive either a single dose of Etavopivat or a placebo. Which treatment the participant gets is decided by chance. In Part B, participants will get four different treatments on four different occasions: Etavopivat in 2 different doses (the new medicine that cannot be prescribed), a dummy medicine (placebo), and an already approved medicine (moxifloxacin). The order of the 4 study medicines is decided by chance. There will be a break of 7 days between each treatment. For Part A, the study duration will be from 10 to 36 days, and for Part B, the study duration will be from 27 to 53 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A minimum of 20% African-American participants will be included in each part of this study.
Efforts will be made to include at least 40 percentage (%) of each sex into each part of the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of etavopivat.
Drug: Etavopivat
Participants will receive a single dose of placebo.
Drug: Placebo
Participants will receive a single dose of etavopivat.
Drug: Etavopivat
Participants will receive a single dose of moxifloxacin.
Drug: Moxifloxacin
Participants will receive a single dose of placebo.
Drug: Placebo
Etavopivat will be administered orally.
Moxifloxacin will be administered orally.
Placebo matching Etavopivat will be administered orally.
Part A: Number of treatment-emergent adverse events (AEs)
Measured as count of events.
Time frame: From dosing (Day 1) until end of study (Day 8)
Part B: Change from baseline in Fridericia heart rate corrected QT interval (ΔQTcF) for etavopivat
Measured as milliseconds.
Time frame: From pre-dose to post etavopivat/ etavopivat placebo dose on day 1 to day 23
Part A: Number of treatment-emergent clinically significant abnormal findings in electrocardiogram (ECGs)
Measured as count of treatment-emergent clinically significant abnormal findings in ECGs.
Time frame: From dosing (Day 1) until end of study (Day 8)
Parts A and B: Cmax,etavopivat- Maximum observed etavopivat plasma concentration after a single dose
Measured as nanograms per milliliter (ng/mL).
Time frame: Day 1 (Part B)/ From day 1 to day 5 (Part A) after investigational medicinal product (IMP) administration
Parts A and B: AUC0-last,etavopivat- Area under the etavopivat plasma concentration-time curve from 0 hours to the time of last quantifiable concentration
Measured as hours\*nanograms per milliliter (h\*ng/mL).
Time frame: Day 1 (Part B)/ From day 1 to day 5 (Part A) after IMP administration
Parts A and B: AUC0-inf,etavopivat- Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose
Measured as h\*ng/mL.
Time frame: Day 1 (Part B)/ From day 1 to day 5 (Part A) after IMP administration
Parts A and B: tmax,etavopivat- Time to maximum observed etavopivat plasma concentration after a single dose
Measured as hours.
Time frame: Day 1 (Part B)/ From day 1 to day 5 (Part A) after IMP administration
Parts A and B: t½ etavopivat- Terminal half-life for etavopivat after a single dose
Measured as hours.
Time frame: Day 1 (Part B)/ From day 1 to day 5 (Part A) after IMP administration
Parts A and B: CL/F etavopivat- Apparent plasma clearance of etavopivat after a single dose
Measured as liters per hour (L/h).
Time frame: Day 1 (Part B)/ From day 1 to day 5 (Part A) after IMP administration
Parts A and B: Vz/F etavopivat- Apparent volume of distribution of etavopivat after a single dose based on plasma concentration values
Measured as liters (L).
Time frame: Day 1 (Part B)/ From day 1 to day 5 (Part A) after IMP administration
Part B: ΔQTcF for moxifloxacin
Measured as milliseconds.
Time frame: From pre-dose to post moxifloxacin dose on day 1 to day 23
Part B: Change from baseline in heart rate (ΔHR). Categorical outliers for HR
Measured as milliseconds.
Time frame: From pre-dose to post etavopivat/ etavopivat placebo dose on day 1 to day 23
Part B: Change from baseline in PR interval (ΔPR). Categorical outliers for PR
Measured as milliseconds.
Time frame: From pre-dose to post etavopivat/ etavopivat placebo dose on day 1 to day 23
Part B: Change from baseline in QRS complex duration (ΔQRS). Categorical outliers for QRS
Measured as milliseconds.
Time frame: From pre-dose to post etavopivat/ etavopivat placebo dose on day 1 to day 23
Part B: Frequency of treatment emergent changes of ECG morphology
Measured as count of treatment emergent changes of ECG morphology.
Time frame: From pre-dose to post etavopivat/ etavopivat placebo dose on day 1 to day 23
Part B: Change from baseline in ΔHR. Categorical outliers for HR
Measured as milliseconds.
Time frame: From pre-dose to post moxifloxacin dose on day 1 to day 23
Part B: Change from baseline in ΔPR. Categorical outliers for PR
Measured as milliseconds.
Time frame: From pre-dose to post moxifloxacin dose on day 1 to day 23
Part B: Change from baseline in ΔQRS. Categorical outliers for QRS
Measured as milliseconds.
Time frame: From pre-dose to post moxifloxacin dose on day 1 to day 23
Part B: Frequency of treatment emergent changes of ECG morphology
Measured as count of treatment emergent changes of ECG morphology.
Time frame: From pre-dose to post moxifloxacin dose on day 1 to day 23
Part B: ΔQTcF for etavopivat
Measured as milliseconds.
Time frame: From pre-dose to post etavopivat/etavopivat placebo dose on day 1 to day 23
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Sep 2025, 3 months.
Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 3 months is below that.
Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etavopivat